Form 4: Moderna Director Noubar Afeyan Sells Shares Under 10b5-1 Trading Plan

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on June 26, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On June 26, 2024, Noubar Afeyan, a director of Moderna, sold shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on February 27, 2023, and amended on November 7, 2023.
• A total of 16,905 shares were sold in multiple transactions at varying prices.
• The prices ranged from $122.27 to $134.05 per share.
• Following the transactions, Afeyan directly owns 2,284,015 shares of Moderna common stock.
• Afeyan also has indirect ownership through Flagship Ventures Fund IV, L.P., Flagship Ventures Fund IV-Rx, L.P., and Flagship Pioneering, Inc.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to insider trading. It doesn't inherently convey positive or negative sentiment, as it simply reports transactions.

Industry Context

Sales by insiders are a common occurrence and are often pre-planned to avoid accusations of trading on inside information. The use of a 10b5-1 plan allows insiders to sell shares at predetermined times and prices.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, potentially leading to a slight decrease in stock price, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates